Literature DB >> 26249010

ICOS regulates the pool of group 2 innate lymphoid cells under homeostatic and inflammatory conditions in mice.

Daniela Paclik1, Christina Stehle1, Annette Lahmann2, Andreas Hutloff2,3, Chiara Romagnani1.   

Abstract

Group 2 innate lymphoid cells (ILC2s) are innate effectors playing an important role in the defense against helminthic infections and in the pathogenesis of allergic inflammation. Cytokines have been identified as the major stimuli driving ILC2 activation and expansion. Conversely, it is unclear whether costimulatory molecules contribute to regulation of ILC2 functions. ILC2s display high expression of inducible T-cell costimulator (ICOS), which belongs to the CD28 superfamily, and which has been shown to control late effector T-cell functions, and is of utmost importance for the humoral immune response. However, the biological function of ICOS expression on ILC2s is unknown. Here, we show that ICOS signaling in mice regulates ILC2 homeostasis independently of T cells and B cells, by promoting proliferation and accumulation of mature ILC2s in lung and intestine. In a model of IL-33-induced airway inflammation, ICOS controls ILC2 activation and eosinophil infiltration in the lung. Our data identify a role of ICOS in innate immunity and indicate that not only cytokines, but also costimulatory pathways such as those involving ICOS, can contribute to regulate the ILC2 pool. Thus, ICOS costimulation blockade, which is currently under clinical evaluation for inhibiting the humoral immune response, could also target innate inflammatory circuits.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  GATA3; ICOS; IL-33; ILC2; Innate lymphoid cell

Mesh:

Substances:

Year:  2015        PMID: 26249010     DOI: 10.1002/eji.201545635

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  42 in total

Review 1.  Cell-surface molecule-mediated cell-cell interactions in the regulation of ILC2-driven allergic inflammation.

Authors:  Aihua Lei; Jie Zhou
Journal:  Cell Mol Life Sci       Date:  2019-07-16       Impact factor: 9.261

2.  IL-33 Signaling in Lung Injury.

Authors:  Jing Chang; Yue-Feng Xia; Ma-Zhong Zhang; Li-Ming Zhang
Journal:  Transl Perioper Pain Med       Date:  2016

Review 3.  Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis.

Authors:  Christoph S N Klose; David Artis
Journal:  Nat Immunol       Date:  2016-06-21       Impact factor: 25.606

Review 4.  The interplay between innate lymphoid cells and T cells.

Authors:  Marie Cherrier; Gayetri Ramachandran; Rachel Golub
Journal:  Mucosal Immunol       Date:  2020-07-10       Impact factor: 7.313

Review 5.  ILC2s in infectious diseases and organ-specific fibrosis.

Authors:  Markus Kindermann; Lisa Knipfer; Imke Atreya; Stefan Wirtz
Journal:  Semin Immunopathol       Date:  2018-03-26       Impact factor: 9.623

Review 6.  Dissecting human ILC heterogeneity: more than just three subsets.

Authors:  Yannick Simoni; Evan W Newell
Journal:  Immunology       Date:  2017-12-26       Impact factor: 7.397

Review 7.  Innate lymphoid cells and allergic disease.

Authors:  Matthew T Stier; R Stokes Peebles
Journal:  Ann Allergy Asthma Immunol       Date:  2017-12       Impact factor: 6.347

8.  Optimal identification of human conventional and nonconventional (CRTH2-IL7Rα-) ILC2s using additional surface markers.

Authors:  Sucai Liu; Kapil Sirohi; Mukesh Verma; Jerome McKay; Lidia Michalec; Anand Sripada; Tomas Danhorn; Donald Rollins; James Good; Magdalena M Gorska; Richard J Martin; Rafeul Alam
Journal:  J Allergy Clin Immunol       Date:  2020-02-04       Impact factor: 10.793

Review 9.  The development of adult innate lymphoid cells.

Authors:  Qi Yang; Avinash Bhandoola
Journal:  Curr Opin Immunol       Date:  2016-02-09       Impact factor: 7.486

Review 10.  Insights into Group 2 Innate Lymphoid Cells in Human Airway Disease.

Authors:  Maya R Karta; David H Broide; Taylor A Doherty
Journal:  Curr Allergy Asthma Rep       Date:  2016-01       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.